Brinzolamide
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Brinzolamide
- Brinzolamide: From an Intraocular Pressure-Lowering Eye Drop to Primary Hereditary Glaucoma
Brinzolamide: From an Intraocular Pressure-Lowering Eye Drop to Primary Hereditary Glaucoma
One-Sentence Summary
Brinzolamide is a carbonic anhydrase inhibitor eye drop marketed in the US. The supplied data lists no original indication, but general pharmacology places it in intraocular pressure (IOP) lowering. The TxGNN model predicts it may be effective for primary hereditary glaucoma, but 0 clinical trials and 0 publications currently support this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in the supplied data (general pharmacology: open-angle glaucoma / ocular hypertension) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.48% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 7 (includes ANDA generic approvals) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the supplied data. Based on general pharmacology, brinzolamide is a carbonic anhydrase II inhibitor. It reduces aqueous humor secretion and lowers intraocular pressure, and it is marketed for open-angle glaucoma and ocular hypertension. This comes from general knowledge, not from the Evidence Pack.
Lowering IOP is biologically plausible for hereditary glaucoma, which is also an IOP-driven optic neuropathy. However, hereditary or congenital glaucoma often involves developmental angle abnormalities (for example CYP1B1 or MYOC variants). In these cases IOP-lowering drugs are usually adjunctive or temporizing rather than definitive treatment.
Two points limit the strength of this prediction:
- The label “primary hereditary glaucoma” may overlap with an existing glaucoma indication, so this may not be true repurposing. This needs to be checked against the missing original-indication data.
- Pediatric safety and efficacy of brinzolamide would need separate confirmation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Five main authorizations are listed below. The approved indication text is not included in the supplied data.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA020816 | Azopt (Sandoz Inc) | Ophthalmic suspension/drops | Not listed in supplied data |
| ANDA204884 | Brinzolamide (Bausch & Lomb Incorporated) | Ophthalmic suspension/drops | Not listed in supplied data |
| ANDA204884 | Brinzolamide (Oceanside Pharmaceuticals) | Ophthalmic suspension/drops | Not listed in supplied data |
| ANDA211914 | Brinzolamide (Padagis US LLC) | Ophthalmic suspension/drops | Not listed in supplied data |
| ANDA211914 | Brinzolamide (Bryant Ranch Prepack) | Ophthalmic suspension/drops | Not listed in supplied data |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score (99.48%) is a computational prediction only, with no clinical trials or literature to support it. Original-indication and mechanism data are missing, and the predicted indication may overlap with an existing glaucoma indication.
To proceed, the following is needed:
- The FDA-approved indication text, to confirm whether “primary hereditary glaucoma” is truly new or already covered
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data (for example from DrugBank)
- A targeted search of clinical trials and literature on brinzolamide in hereditary or congenital glaucoma, including pediatric data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.